N. M. U. Sultanbaeva

N. M. U. Sultanbaeva

Auto-generated profile, based on publicly available information

N. M. U. Sultanbaeva

Institute of Pharmaceutical Education and Research

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
AIA. B. Ismoilova
A. B. Ismoilova
NSN. M.U. Sultanbaeva
N. M.U. Sultanbaeva
AAA. A. Abdurakhmanov
A. A. Abdurakhmanov
SUSh. Z. Umarova
Sh. Z. Umarova
DDD. Kh. Dzhalalova
D. Kh. Dzhalalova
SDS. Ch. Dzhalalov
S. Ch. Dzhalalov
Objective: comparative systematic analysis of clinical trials of staged and simultaneous approaches in the surgical treatment of combined carotid and coronary stenosis based on the literature search.Material and methods. A systematic literature search was performed in PubMed/MEDLINE, Google Scholar and Scopus using predefined acceptance criteria. To compare data of simultaneous and staged surgery cumulative indicators of heart attack, stroke and mortality, expressed as percentages and absolute numbers, were analyzed; the Mantel–Hensel formula and the χ2 method were used to assess the relative risk of major adverse cardio-cerebral events development and mortality.Results. The analysis included 7 studies containing one intervention (4 simultaneous and 3 stage methods). The risk of developing myocardial infarction was RR 0.13 (95% CI 0.02–0.67) for simultaneous tactics, and RR 7.79 (95% CI 1.5–40.43) for staged tactics (p˂0.005). The risk of stroke developing was RR 1.29 (95% CI 0.56–2.99) for a simultaneous approach, and RR 0.78 (95% CI 0.33–1.8) for stage approach (p˃0.05). The risk of mortality was RR 0.77 (95% CI 0.31–1.88) for simultaneous procedures, and RR 1.3 (95% CI 0.53–3.18) for staged procedures (p˃0.05).Conclusion. Staged tactics for combined carotid and coronary stenosis may be accompanied by a significantly higher risk of myocardial infarction. There was no statistically significant difference between the groups in terms of the risk of stroke and mortality, but there was a trend towards a higher risk of stroke in the simultaneous group and a higher risk of death from all causes in the staged group.

22 January 2026 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
NSN. M. U. Sultanbaeva
N. M. U. Sultanbaeva
DSD. U. Saydaliyeva
D. U. Saydaliyeva
SUSh. Z. Umarova
Sh. Z. Umarova
Background. Nootropics are pharmacological agents that enhance such cognitive functions as memory and attention, as well as the overall mental performance. In recent years, global demand for these pharmaceuticals has significantly increased due to intensified psychological stress, a growing incidence of neurological disorders, and a growing public focus on mental health. In Uzbekistan, the nootropic drug market is experiencing active growth, underscoring the need for a comprehensive analysis of its structure and key trends. Objective: To analyze trends in the nootropic drug market in Uzbekistan from 2015 to 2024, to identify key trends and factors influencing its development, and to assess the dynamics of supply and demand. Material and methods. The available data on registered nootropic drugs in Uzbekistan, pharmaceutical company reports, sales statistics, and information on government policy and support measures were used. The dynamics of the number of registered trade names and their distribution by manufacturing country were studied. Leading companies playing a key role in the market were identified. The distribution of nootropics by composition (monodrugs and combination forms) and dosage forms (oral, injectable, etc.) was also examined. Results. The analysis revealed a steady growth in the nootropic drug market in Uzbekistan throughout the study period. This growth is primarily driven by the increasing demand for cognitive enhancers across various age groups. One evident trend consists in the expanding presence of domestic manufacturers, who are introducing novel drug forms, including combination and injectable formulations. Additionally, innovative compounds, such as citicoline that has shown considerable therapeutic potential across various neurological conditions, are increasingly attracting attention. Conclusion. The nootropic drug market in Uzbekistan is demonstrating positive growth dynamics, driven by rising consumer demand and reinforced by supportive government initiatives. The market is expected to continue to grow, with improvements in drug variety and accessibility. Both local and international pharmaceutical companies play a pivotal role in enhancing product quality and ensuring broad patient access.

1 July 2025 in Social Pharmacy in Health Care
Verified
Journal Article
Open access
PDF file
DSD.U. Saydalieva
D.U. Saydalieva
NSN.M.U. Sultanbaeva
N.M.U. Sultanbaeva
The increasing incidence of cerebrovascular and cognitive disorders in Uzbekistan, driven by a growing information load and an aging population, has led to a heightened demand for effective nootropic medications. The pharmaceutical market is adapting to this demand through a diversified range of drugs, including both imported and domestically produced products. Aim. This study aims to evaluate the dynamics of the nootropic drug market in the Republic of Uzbekistan from 2015 to 2024 in both physical and monetary terms, including the analysis of import volumes, domestic production, key market players, dosage forms, and trends in international nonproprietary names. Materials and methods. The study utilized aggregated data on the registration, import, and production of nootropic drugs classified under ATC group N06BX. Marketing analysis methods and qualimetric tools were applied to identify quantitative trends, structural shifts over the study period. Results and discussion. The article presents an analysis of the dynamics of the nootropic drug market in the Republic of Uzbekistan over the period 2015–2024. It examines quantitative changes in both physical and monetary terms, as well as the structure of imports and domestic production. Key trends are identified, including an increase in nootropic consumption up to 2022 followed by a subsequent decline, the strengthening of domestic manufacturers' positions, and changes in the assortment and consumption structure by international nonproprietary names. A comparative analysis of supplies from CIS and non-CIS countries is provided, along with an evaluation of the activity of leading domestic companies. Particular attention is given to dosage forms. The findings of the study may be used to assess the current state of the pharmaceutical market and to inform strategic planning for the development of the nootropic drug sector in Uzbekistan. Conclusions The nootropic drug market in Uzbekistan shows cyclical dynamics with strong domestic development potential. Market fluctuations reflect clinical guideline revisions and increased emphasis on evidence-based prescribing. The study highlights the growing role of local manufacturers and the shift toward more complex and effective nootropic formulations.

29 May 2026 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
NSN.M. U. Sultanbaeva
N.M. U. Sultanbaeva
SUSh. Z. Umarova
Sh. Z. Umarova
SISh. F. Iskandarova
Sh. F. Iskandarova
Background . No systematic data are currently available on long-term trends in the product range, prices, and supply structure of antithrombotic drugs in the Republic of Uzbekistan, which hinders pharmaceutical supply planning. Objective:   To conduct a comprehensive analysis of the antithrombotic drug market in the Republic of Uzbekistan covering the period 2010–2024. Materials and methods. This study presents the first multi-parametric analysis of the antithrombotic drug market in the Republic of Uzbekistan over a 15-year period. The analysis evaluated registration trends, supply volumes, price ranges, manufacturing countries, and the pharmacoeconomic characteristics of antithrombotic agents. Data were obtained from the State Register of Medicines, Medical Devices, and Medical Equipment, published by the Ministry of Health of the Republic of Uzbekistan, as well as the Drugs Audit system. Methodological approaches included product range analysis, trend analysis, price analysis, calculation of the compound annual growth rate (CAGR), and correlation analysis (Pearson correlation coefficient, p<0.05). Results. The assortment of antithrombotic drugs expanded from 53 to 141 trade names over the period under review, with an average of approximately 50% entering active commercial circulation. Supply volumes increased 6.6-fold, peaking at 12.19 million packages (2020), followed by a decline (CAGR: −8.03%). Although imported products account for 83% of the product range, the share of domestic manufacturers has increased since 2017. The leading International Nonproprietary Names in the market include acetylsalicylic acid, enoxaparin, and clopidogrel; the market share of rivaroxaban is growing. Conclusion. The antithrombotic drug market in the Republic of Uzbekistan has become more diversified, yet it remains import-dependent. The findings of this study can be used to inform public policy and procurement planning.

7 May 2026 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
NSN. M. U. Sultanbaeva
N. M. U. Sultanbaeva
SUSh. Z. Umarova
Sh. Z. Umarova
Background . Beta-adrenergic blockers, or beta-blockers (BBs), are a crucial class of medications. Given their extensive use in the management of cardiovascular diseases, regular analysis of BB availability and range in the pharmaceutical market is essential. Objective : To analyze the range of BBs available on the pharmaceutical market of the Republic of Uzbekistan, taking their quantitative composition, countries of origin, and dosage forms into account. Material and methods . The study utilized data from the State Register of medicines, medical devices and medical equipment approved for use in medical practice in the Republic of Uzbekistan. Methods employed included systematization, statistical and comparative analysis, and graphical representation of the results. Results . The Uzbek pharmaceutical market is dominated by metoprolol, bisoprolol, and nebivolol, with the majority of products manufactured in the countries of the near and far abroad such as India, Russia, and Germany. Solid dosage forms, specifically tablets and capsules, are prevalent in this sector, which is consistent with the therapeutic use of this drug class. Conclusion . The range of BBs in the pharmaceutical market of Uzbekistan is extensive in terms of international nonproprietary names, trade names, and manufacturing origins. This reflects consistent demand and the clinical importance of this drug group in the management of cardiovascular conditions. The findings can be used to further improve the pharmaceutical supply system.

9 April 2026 in Current Cardiology Reviews
Verified
Journal Article
Closed access
PDF file
SNSultanbaeva Nargiza
Sultanbaeva Nargiza
MSMukhamedova Shohista
Mukhamedova Shohista
USUmarova Shakhnoz
Umarova Shakhnoz
MGMullabaeva Guzal
Mullabaeva Guzal
Introduction: To evaluate the cost-effectiveness of empagliflozin in patients with chronic heart failure with preserved ejection fraction (CHFpEF) and moderately reduced ejection fraction (CHFmrEF) across various healthcare systems. Materials and Methods: A systematic review was conducted according to PRISMA 2024 guidelines. A total of 6 studies were included after screening 225 records from PubMed, Web of Science, ScienceDirect, and Google Scholar. Studies evaluating cost-effectiveness outcomes, including incremental cost-effectiveness ratios (ICER), quality-adjusted life years (QALY), and healthcare costs, were analyzed. Results: All included studies applied a Markov model over a 10-year time horizon. Empagliflozin was associated with a 15–18% reduction in hospitalizations, an increase in QALYs by 0.11–0.67, and ICERs ranging from €5,089/QALY to $174,053/QALY, depending on the healthcare setting and model assumptions. Examples include: Spain: €5,089/QALY, China: $11,292/QALY, USA: $25,974–$174,053/QALY, Australia: A$29,202/QALY. ICER per life year (LY) ranged from $6,246 to $151,929, indicating variable cost-effectiveness based on country-specific cost structures and thresholds. Conclusions: Empagliflozin appears to be a cost-effective add-on therapy to standard care for CHFpEF and CHFmrEF, especially in healthcare systems with high hospitalization costs. However, its value is highly sensitive to drug pricing and national willingness-to-pay thresholds. Further real-world studies are needed to confirm long-term economic benefits. The review was registered with PROSPERO (CRD420250654439). Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420250654439.